{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HA+Treatment",
    "query": {
      "intervention": "HA Treatment"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 87,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HA+Treatment&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-04T03:23:42.556Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02415842",
      "title": "A Laboratory Evaluation of the Humoral Immune Response in Adults and Children to the H1 Hemagglutinin (HA) Stalk Domain and Other Influenza A Virus Protein Epitopes, After Administration of GlaxoSmithKline (GSK) Biologicals' Pandemic Influenza Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Immunologic Tests"
      ],
      "interventions": [
        {
          "name": "Serum samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "6 Months to 64 Years"
      },
      "enrollment_count": 414,
      "start_date": "2015-10-26",
      "completion_date": "2018-02-16",
      "has_results": true,
      "last_update_posted_date": "2019-07-23",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02415842"
    },
    {
      "nct_id": "NCT05634720",
      "title": "Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pancreatic Ductal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "HA Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-01-02",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05634720"
    },
    {
      "nct_id": "NCT03712137",
      "title": "Study of the Safety and Effectiveness of JUVÉDERM VOLUX™ XC Injectable Gel for Restoring Jawline Definition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Jawline Definition"
      ],
      "interventions": [
        {
          "name": "VOLUX XC",
          "type": "DEVICE"
        },
        {
          "name": "No-treatment control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 206,
      "start_date": "2018-11-12",
      "completion_date": "2021-01-26",
      "has_results": true,
      "last_update_posted_date": "2023-01-04",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 14 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03712137"
    },
    {
      "nct_id": "NCT06840015",
      "title": "Use of Airpod Pros as Assistive Technology",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hearing Loss, Adult-Onset",
        "Hearing Aids"
      ],
      "interventions": [
        {
          "name": "Airpod Pro as hearing assistive technology",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "The University of Texas at Dallas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 24,
      "start_date": "2025-07-01",
      "completion_date": "2026-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 1,
      "location_summary": "Richardson, Texas",
      "locations": [
        {
          "city": "Richardson",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06840015"
    },
    {
      "nct_id": "NCT02753595",
      "title": "Study of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Eribulin mesylate",
          "type": "DRUG"
        },
        {
          "name": "Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)",
          "type": "OTHER"
        },
        {
          "name": "Biologic: PEGylated recombinant human hyaluronidase",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Eisai Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2016-07-13",
      "completion_date": "2019-08-16",
      "has_results": true,
      "last_update_posted_date": "2020-07-13",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 7,
      "location_summary": "Whittier, California • Atlanta, Georgia • Newnan, Georgia + 4 more",
      "locations": [
        {
          "city": "Whittier",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "Anderson",
          "state": "Indiana"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02753595"
    },
    {
      "nct_id": "NCT05867602",
      "title": "High Dose Albumin in Refractory Ascites",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ascites"
      ],
      "interventions": [
        {
          "name": "Albumin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2019-03-25",
      "completion_date": "2027-06-25",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05867602"
    },
    {
      "nct_id": "NCT02195427",
      "title": "TEOSYAL® RHA Global Action, TEOSYAL® RHA Deep Lines, and Juvéderm® Ultra XC for the Correction of Nasolabial Folds",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nasolabial Folds, Wrinkles"
      ],
      "interventions": [
        {
          "name": "TEOSYAL® RHA Global Action",
          "type": "DEVICE"
        },
        {
          "name": "TEOSYAL® RHA Deep Lines",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Teoxane SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2014-06",
      "completion_date": "2016-03",
      "has_results": true,
      "last_update_posted_date": "2018-04-25",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Beverly Hills, California • Santa Monica, California + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02195427"
    },
    {
      "nct_id": "NCT03313934",
      "title": "Platelet Rich Fibrin for Tear Trough Rejuvenation",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Tear Trough Hollowing, Under Eye Bags"
      ],
      "interventions": [
        {
          "name": "Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Hyaluronic Acid Filler and Saline",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Rejuva Medical Aesthetics",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "20 Years to 80 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-11",
      "completion_date": "2018-11",
      "has_results": false,
      "last_update_posted_date": "2017-10-18",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03313934"
    },
    {
      "nct_id": "NCT04231318",
      "title": "Study of Cingal® and Triamcinolone Hexacetonide for the Relief of Knee Osteoarthritis Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Osteoarthritis, Knee"
      ],
      "interventions": [
        {
          "name": "Cingal",
          "type": "DRUG"
        },
        {
          "name": "Triamcinolone Hexacetonide (TH)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anika Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 231,
      "start_date": "2020-09-11",
      "completion_date": "2022-05-16",
      "has_results": true,
      "last_update_posted_date": "2023-08-09",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 26,
      "location_summary": "Chandler, Arizona • Tucson, Arizona • Anaheim, California + 21 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Covina",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04231318"
    },
    {
      "nct_id": "NCT06153940",
      "title": "Everglade Stem, World Cup and World Liner Post Market Clinical Follow-up",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hip Disease"
      ],
      "interventions": [
        {
          "name": "Treatment",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Signature Orthopaedics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 200,
      "start_date": "2023-11-22",
      "completion_date": "2028-03-01",
      "has_results": false,
      "last_update_posted_date": "2023-12-01",
      "last_synced_at": "2026-09-04T03:23:42.556Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06153940"
    }
  ]
}